Difference between revisions of "Lung carcinoma with EGFR mutation"
Jump to navigation
Jump to search
Line 4: | Line 4: | ||
*EGFR mutations are most closely associated with [[lung adenocarcinoma]]. | *EGFR mutations are most closely associated with [[lung adenocarcinoma]]. | ||
*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | *Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | ||
Varies significantly by population:<ref name=pmid27738317>{{Cite journal | last1 = Zhang | first1 = YL. | last2 = Yuan | first2 = JQ. | last3 = Wang | first3 = KF. | last4 = Fu | first4 = XH. | last5 = Han | first5 = XR. | last6 = Threapleton | first6 = D. | last7 = Yang | first7 = ZY. | last8 = Mao | first8 = C. | last9 = Tang | first9 = JL. | title = The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. | journal = Oncotarget | volume = 7 | issue = 48 | pages = 78985-78993 | month = Nov | year = 2016 | doi = 10.18632/oncotarget.12587 | PMID = 27738317 }}</ref> | |||
{| class="wikitable sortable" | |||
! Population | |||
! Prevalence | |||
! Category | |||
|- | |||
| Europe | |||
| 14% | |||
| Geographic | |||
|- | |||
| China | |||
| 38% | |||
| Geographic | |||
|- | |||
| Females | |||
| 44% | |||
| Patient characteristics | |||
|- | |||
| Males | |||
| 24% | |||
| Patient characteristics | |||
|- | |||
| Non-smokers | |||
| 49% | |||
| Patient characteristics | |||
|- | |||
| Smokers or past smokers | |||
| 22% | |||
| Patient characteristics | |||
|- | |||
| Adenocarcinoma | |||
| 38% | |||
| Pathology | |||
|- | |||
| Non-adenocarcinoma | |||
| 12% | |||
| Pathology | |||
|} | |||
==Sign out== | ==Sign out== |
Revision as of 17:42, 18 June 2017
Lung adenocarcinoma with EGFR rearrangement is a molecular subtype of lung adenocarcinoma.
General
- EGFR mutations are most closely associated with lung adenocarcinoma.
- Testing indicated in non-small cell carcinoma, adenosquamous carcinoma of the lung, as well as lung adenocarcinoma.
Varies significantly by population:[1]
Population | Prevalence | Category |
---|---|---|
Europe | 14% | Geographic |
China | 38% | Geographic |
Females | 44% | Patient characteristics |
Males | 24% | Patient characteristics |
Non-smokers | 49% | Patient characteristics |
Smokers or past smokers | 22% | Patient characteristics |
Adenocarcinoma | 38% | Pathology |
Non-adenocarcinoma | 12% | Pathology |
Sign out
Lung core biopsy, left lower lobe: - EGFR mutation POSITIVE, ALK rearrangement NEGATIVE
See also
References
- ↑ Zhang, YL.; Yuan, JQ.; Wang, KF.; Fu, XH.; Han, XR.; Threapleton, D.; Yang, ZY.; Mao, C. et al. (Nov 2016). "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.". Oncotarget 7 (48): 78985-78993. doi:10.18632/oncotarget.12587. PMID 27738317.